The utility of buparlisib as an effective therapeutic agent is also influenced by the prevalence of activating PIK3CA mutations in sarcoma since increased single agent sensitivity is observed for tumors harboring these mutations [21]. The gene discussed is PIK3CA; the disease is sarcoma.